Breaking News Instant updates and real-time market news.

BMRN

BioMarin

$81.99

1.09 (1.35%)

, ALXN

Alexion

$114.46

7.68 (7.19%)

19:11
12/10/17
12/10
19:11
12/10/17
19:11

Piper Jaffray remains bullish on BioMarin, Alexion following ASH

Piper Jaffray analyst Christopher Raymond remains Overweight rated on BioMarin (BMRN) and Alexion (ALXN), and Neutral rated on Celgene (CELG) following the American Society of Hematology Annual Meeting. Most notably, the analyst finds BioMarin's hemophilia gene therapy data with longer term data to be most impactful.

BMRN

BioMarin

$81.99

1.09 (1.35%)

ALXN

Alexion

$114.46

7.68 (7.19%)

CELG

Celgene

$106.09

3.36 (3.27%)

  • 10

    Dec

  • 10

    Dec

  • 08

    Jan

  • 18

    Jan

  • 28

    Feb

  • 25

    Mar

BMRN BioMarin
$81.99

1.09 (1.35%)

10/19/17
FBCO
10/19/17
NO CHANGE
Target $124
FBCO
Outperform
BioMarin price target raised to $124 from $114 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for BioMarin to $124 from $114 as she believes there is a higher chance of success for hemophilia A gene therapy. The analyst reiterates an Outperform rating on the shares.
10/06/17
GSCO
10/06/17
INITIATION
Target $124
GSCO
Buy
BioMarin resumed with a Buy at Goldman Sachs
Goldman analyst Salveen Richter resumed coverage on BioMarin with a Buy and $124 price target.
10/18/17
PIPR
10/18/17
NO CHANGE
Target $113
PIPR
Overweight
Piper says BioMarin weakness after 'positive' R&D day a buying opportunity
Piper Jaffray analyst Christopher Raymond said the number one question he is receiving following BioMarin's "decidedly positive" R&D day has been "why is the stock down?" He suggests it may be a "sell-the-news" reaction to the event and recommends buying on today's weakness, given that he believes "significant meaningful progress" was communicated during the event. Raymond keeps an Overweight rating and $113 price target on BioMarin shares, which are down 5% to $89 in late day trading.
10/19/17
LEER
10/19/17
NO CHANGE
Target $142
LEER
Outperform
BioMarin price target raised to $142 from $136 at Leerink
Leerink analyst Joseph Schwartz raised his price target for BioMarin to $142 from $136 after management provided encouraging updates on key programs BMN270, BMN111/vosoritide, BMN165/pegvaliase, BMN250, unveiled a new program BMN290 for Friedreich's Ataxia, and discussed weak sales in Brazil leading to lower Q3 revenues. The analyst also increased his PoS for pegvaliase to 85% from 60%. He reiterates an Outperform rating on the shares.
ALXN Alexion
$114.46

7.68 (7.19%)

12/04/17
JEFF
12/04/17
NO CHANGE
Target $25
JEFF
Buy
RA Pharmaceuticals selloff 'way too overdone,' says Jefferies
Jefferies analyst Eun Yang views the post-Phase 2 data selloff today in shares of RA Pharmaceuticals (RARX) as overreaction. The interim data show RA's RA101495 is an active and approvable product with efficacy as good as Alexion's (ALXN) Soliris, Yang tells investors in an intraday research note. While RA101495 may not be suitable for the 20% of Soliris patients that are transfusion dependent, the 37% selloff in the stock today is "way too overdone," the analyst contends. Yang sees "significant upside potential" in RA shares even at "modest market share of Soliris." She keeps a Buy rating on RA Pharmaceuticals with a $25 price target. The stock in midday trading is down $5.34 to $8.89.
12/06/17
LEER
12/06/17
NO CHANGE
Target $169
LEER
Outperform
Leerink positive on upcoming Alexion '1210 phase 3 results in PNH
Leerink analyst Geoffrey Porges has a "strongly positive view" about the upcoming Q2 2018 Alexion's ALXN1210 phase III results in paroxysmal nocturnal hemoglobinuria, or PNH. The analyst expects ALXN1210 to meet its primary endpoint of non-inferiority to Soliris and also to be superior to Soliris. Further, Porges believes investors should expect the phase III ALXN1210 results to show LDH normalization in 70%-80% of patients, compared to less than30% for Soliris, and for transfusion avoidance he expects ALXN1210 to reach 80% and Soliris to be 50%. He reiterates an Outperform rating and $169 price target on the shares.
11/06/17
PIPR
11/06/17
NO CHANGE
Target $170
PIPR
Overweight
Alexion IP extension efforts 'right on schedule,' says Piper Jaffray
Soliris' news today that its intellectual property in Japan has been extended through 2027, just a few months after the same was achieved in the U.S., shows its IP extension efforts "appear to be right on schedule," Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst remains remain confident that Soliris will maintain its exclusivity for the next 10 years, despite biosimilar challengers. He keeps an Overweight rating on Alexion Pharmaceuticals with a $170 price target.
12/04/17
12/04/17
NO CHANGE
Target $170

Overweight
RA data 'underwhelms' compared to Alexion's Soliris, says Piper Jaffray
Today's paroxysmal nocturnal hemoglobinuria data from RA Pharmaceuticals (RARX) "underwhelms on efficacy" in comparison to Alexion's (ALNX) Soliris "and for that matter" ALXN1210, Piper Jaffray analyst Christopher Raymond tells investors in a research note titled "Remind Us Again... Why Are We Worried About Ra Pharmaceuticals?" The analyst believes inferior efficacy to Soliris should put "to bed" the treat from RA, and he reminds investors that ALXN1210 "should raise the bar from a convenience standpoint." The analyst sees "little reason to fret" at this point over the competitive threat to Alexion from RA101495. Raymond keeps an Overweight rating on Alexion with a $170 price target.
CELG Celgene
$106.09

3.36 (3.27%)

11/20/17
JEFF
11/20/17
NO CHANGE
Target $125
JEFF
Buy
Celgene shares can rebound to $125 in 12-18 months, says Jefferies
After hosting investor meetings with management, Jefferies analyst Michael Yee is more positive on his view that Celgene (CELG) shares can rebound to $125 over the next 12-18 months. The biotech closed Friday up 75c to $104.10. The company could generate "a conservative" $50B in free cash flow in the next five year even before Revlimid starts eroding in 2022, Yee tells investors in a research note. As such, management "can easily deploy the balance sheet" and bring in one or a few late-stage assets to diversify and ease investor concerns, the analyst adds. Yee thinks PARP inhibitors like Clovis Oncology (CLVS) "fit that mold and that's a good first step." The analyst has a Buy rating on Celgene with a $125 price target.
12/05/17
ADAM
12/05/17
INITIATION
Target $202
ADAM
Buy
bluebird bio initiated with a Buy at Canaccord
Canaccord analyst John Newman initiated bluebird bio (BLUE) with a Buy rating citing its partnership with Celgene (CELG) and the long-term potential of bb2121, which could be used as an alternative or substitute for stem cell transplant in multiple myeloma. He also noted its improved process for its gene therapy product in addition to its drug pipeline. Newman has a $202 price target on bluebird bio shares.
12/08/17
ATLE
12/08/17
UPGRADE
ATLE
Overweight
Celgene upgraded to Overweight from Neutral at Atlantic Equities
12/08/17
JEFF
12/08/17
NO CHANGE
Target $125
JEFF
Buy
Jefferies positive on Celgene ahead of ASH conference
Jefferies analyst Michael Yee believes this weekend's American Society of Hematology conference should showcase Celgene's (CELG) CAR-T pipeline and possibly its PD-1 strategy. Further, the analyst sees Roche's (RHHBY) chemo-combo study as an incremental benefit. He notes that Roche's IMpower 130 and 131, which readout in the first half of 2018, both use Celgene's Abraxane as part of the chemo-combo instead of paclitaxel. Yee expects these trials to be positive as well, which should prove that Abraxane can be a chemo of choice in the chemo-combo regimens. Celgene is a "very reasonable" turnaround play for 2018, Yee tells investors in a research note. He believes the recent selloff is an overreaction and creates a buying opportunity "in time." The analyst has a Buy rating on the shares with a $125 price target.

TODAY'S FREE FLY STORIES

MTB

M&T Bank

$174.38

5.77 (3.42%)

07:20
07/19/18
07/19
07:20
07/19/18
07:20
Recommendations
M&T Bank analyst commentary  »

M&T Bank price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:20
07/19/18
07/19
07:20
07/19/18
07:20
General news
Treasury Market Outlook: Treasury yields have extended slightly higher »

Treasury Market Outlook:…

WRD

WildHorse Resource

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
WildHorse Resource initiated  »

WildHorse Resource…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 19

    Aug

ARA

American Renal Associates

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
American Renal Associates initiated  »

American Renal Associates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BIG

Big Lots

$42.76

0.39 (0.92%)

07:19
07/19/18
07/19
07:19
07/19/18
07:19
Initiation
Big Lots initiated  »

Big Lots initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:18
07/19/18
07/19
07:18
07/19/18
07:18
General news
Futures lower as trade war rhetoric, earnings reporting continues »

Stock futures are…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

, VIAV

Viavi

$10.39

-0.09 (-0.86%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Recommendations
Lumentum, Viavi, Apple analyst commentary  »

JPMorgan raises 3D…

LITE

Lumentum

$59.30

-0.05 (-0.08%)

VIAV

Viavi

$10.39

-0.09 (-0.86%)

AAPL

Apple

$190.43

-1.12 (-0.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 14

    Aug

HNHPF

Hon Hai Precision

$0.00

(0.00%)

07:17
07/19/18
07/19
07:17
07/19/18
07:17
Periodicals
Foxconn interested in webcast business opportunities, DigiTimes reports »

Foxconn has been building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$102.98

1.84 (1.82%)

07:15
07/19/18
07/19
07:15
07/19/18
07:15
Recommendations
American Express analyst commentary  »

American Express Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

07:15
07/19/18
07/19
07:15
07/19/18
07:15
General news
FX Update: The Dollar rose for at third consecutive day »

FX Update: The Dollar…

KEY

KeyCorp

$20.30

0.24 (1.20%)

07:14
07/19/18
07/19
07:14
07/19/18
07:14
Hot Stocks
KeyCorp sees FY18 net interest income $3.95B-$4.05B, one rate increase »

For loans, the company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

  • 30

    Oct

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

, AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

07:14
07/19/18
07/19
07:14
07/19/18
07:14
Upgrade
Use LGF.A, LGF.B, Amazon.com, Alphabet Class A rating change  »

Lionsgate upgraded to Buy…

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

AMZN

Amazon.com

$1,842.36

-1.64 (-0.09%)

GOOGL

Alphabet Class A

$1,212.64

-1.01 (-0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 26

    Jul

  • 16

    Aug

  • 18

    Sep

TGT

Target

$76.86

-0.385 (-0.50%)

07:11
07/19/18
07/19
07:11
07/19/18
07:11
Hot Stocks
Target, Shipt launch same-day delivery in Greater New York Metro »

Shipt and Target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$82.16

-0.17 (-0.21%)

07:11
07/19/18
07/19
07:11
07/19/18
07:11
Earnings
Philip Morris lowers FY18 currency-neutral net revenue growth view to 3%-4% »

PMI revised its 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

RCI

Rogers Communications

$50.94

0.45 (0.89%)

07:10
07/19/18
07/19
07:10
07/19/18
07:10
Hot Stocks
Rogers Communications reports strong subscriber performance in Wireless in Q2 »

Reports: Service revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

07:10
07/19/18
07/19
07:10
07/19/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.19

-0.02 (-1.65%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Hot Stocks
Paramount Gold Nevada receives approval for fifth baseline data report »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PM

Philip Morris

$82.16

-0.17 (-0.21%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Earnings
Philip Morris lowers FY18 EPS view to $5.02-$5.12, consensus $5.15 »

Had seen FY18 EPS of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

GDX

Market Vector Gold Miners

$21.88

(0.00%)

07:09
07/19/18
07/19
07:09
07/19/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTX

United Technologies

$131.69

0.98 (0.75%)

, EADSY

Airbus

$0.00

(0.00%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Hot Stocks
CALC orders Pratt & Whitney GTF engines for Airbus A320neo aircraft »

Pratt & Whitney, a…

UTX

United Technologies

$131.69

0.98 (0.75%)

EADSY

Airbus

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

FUL

H.B. Fuller

$55.97

0.58 (1.05%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Conference/Events
H.B. Fuller to host analyst and investor day »

Analyst and Investor Day…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

RCI

Rogers Communications

$50.94

0.45 (0.89%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Earnings
Rogers Communications reports Q2 EPS C$1.07, consensus C$1.05 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$116.28

-0.005 (-0.00%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Technical Analysis
SPDR Gold Trust: Pivot points, pivot low broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

POOL

Pool Corp.

$157.49

-0.33 (-0.21%)

07:08
07/19/18
07/19
07:08
07/19/18
07:08
Earnings
Pool Corp. narrows FY18 EPS view to $5.50-$5.70 from $5.45-$5.70 »

Consensus is $5.56. The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

IBM

IBM

$144.44

0.98 (0.68%)

07:07
07/19/18
07/19
07:07
07/19/18
07:07
Recommendations
IBM analyst commentary  »

IBM price target lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.